Covid-19 Update

Hilary Benn Excerpts

Wednesday 8th December 2021 Commons Chamber

[Sajid Javid]

That is a very fair question, and it requires a full explanation. There is new data since I was last at this Dispatch Box on the rate and growth in transmissibility, and there is new data, to which I referred in my statement, on the impact of the variant on vaccines. My right hon. Friend will know that if the vaccines were even a little bit less effective, especially against severe disease and therefore against hospitalisation, and if there was also a hugely growing infection rate, a smaller percentage of what would be a much larger number would still result in significant hospitalisations.

[Hilary Benn (Leeds Central) (Lab)]

Could the Secretary of State tell the House what his understanding is of the development of a new vaccine specifically to target omicron and when it might be available? Secondly, can he tell us what the latest evidence is on the protection against this new variant that two doses plus the booster will give to people?

[Sajid Javid]

From the moment they learned about omicron, the vaccine manufacturers, particularly those that make the so-called mRNA-type vaccines, started work on new omicron-targeting vaccines. It is hard to put a timing on this, not least because the companies themselves are unable to, but it is reasonable to think that they can move very quickly. Some of the conversations I have had suggest that they may well be able to have vaccines ready for trial within weeks. There would obviously have to be a trial to ensure that they were safe and effective, but there may be cases where they could be used in emergency situations. On the question about the two doses and a booster, we do not have reliable data on that at this point. However, the information I referred to in my statement on the impact of vaccinations showed that South Africans, in this case, who had had two doses of the vaccine and who had also had an infection had a higher level of protection than those who had not had an infection. This suggests that that hybrid outcome, where someone has had an infection and two doses, is not too dissimilar from having a booster shot and that it had a positive outcome.